Epilepsy
Conditions
Keywords
Safety, Electrodes, Device, StereoElectroencephalograph, Epileptogenic zone, Fast ripples
Brief summary
The main objective of this study is to evaluate the feasibility of recording fast-ripples, a potential new biomarker of epilepsy, using the new micro-macroelectrodes developed by Dixi-Medical.
Detailed description
Partial epilepsies are refractory to medical treatment in 30% of the cases (Refractory Partial Epilepsy or RPE). Patients with RPE suffer from social and occupational disability, an increased risk associated with seizures (traumatic brain injury, accidents), but also a higher risk of sudden unexplained death (2 to 3 times higher) than the general population. Moreover, the medical and social burden of these patients is heavy, representing a significant cost to society. In some cases, surgical treatment with resection of the epileptogenic zone (EZ) can be proposed. The presurgical evaluation includes various investigations seeking to clarify the location of the EZ; but this approach is sometimes insufficient and the definition of the EZ then requires invasive exploration through intracerebral EEG recording (stereo-EEG, SEEG). This latter technique is currently the preferred standard to define the EZ. It involves implanting electrodes in the brain areas suspected to belong to the seizure network. 50 to 70% of patients investigated with this technique will have epilepsy surgery. In recent years, a series of studies in animals and humans have suggested that some oscillations, very short and at very high frequency (\> 250 Hz), called "fast ripples" (FRs) could be a good biomarker of the EZ (for a review see Zijlmans et al, 2012). The FRs are more easily recorded from microelectrode (diameter: 20-40 microns). The purpose of this study is to evaluate a new medical device designed by DixiMedical to record FRs, combining micro and regular clinical electrodes.
Interventions
DEVICEintracerebral micro-macroelectrodes
All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
Sponsors
University Hospital, Toulouse
CerCo, CNRS Cerco UMR5549 CHU Purpan Toulouse France
DIXI Medical, Besançon, France
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patient with RPE in whom SEEG is required to precisely localize the seizure focus
Exclusion criteria
Patients with SEEG contra-indication: * severe psychiatric disorders, * severe agitation during their crisis * contraindication for performing an MRI: claustrophobia, a cardiac or neural stimulator, ferromagnetic surgical clips, cochlear implants, intraocular metallic foreign body or in the nervous system, * contraindication to intracerebral investigation (macro-electrodes): ongoing infection, severe associated pathology (cardiac, pulmonary, renal, hepatic), pregnant or nursing women, * anti thrombotic ongoing treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the feasibility of recording Fast Ripples (FRs) | During 5 days | Proportion of patients who are registered more than 60 FRs per hour the day 3 and the day 4 on the micro-macro electrode in the presumed epileptogenic zone, compared to the number of patients included |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the interest of FRs | During 5 days | Sum of FRs recorded over the 5 days. |
| Evolution of the hourly frequency of FRs | During 5 days | The evolution of the hourly frequency of FRs recorded by the microelectrodes depending on the day of recording. |
| Effectiveness of microelectrodes and macroelectrodes | During 5 days | Number of FRs stored on the macro-blocks immediately adjacent to the microelectrodes located in the EZ. |
| safety of micro-macroelectrodes | During 5 days | A quantitative and qualitative description of the side effects associated with the procedure. |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORluc valton, MD
University Hospital, Toulouse
Outcome results
None listed